Table 1.
Baseline characteristics, clinical data and main laboratory results.
| Patient | Age (yr) | Sex | Day of symptoms* | Oxygen therapy |
Laboratory results at imatinib onset |
Other therapies | Days of hospitalization | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 of imatinib | Highest† | C-reactive protein (mg/dL) | Interleukin-6 (pg/mL) | Lymphocyte count (x109/L) | D-dimer (ng/mL) | ||||||
| 1 | 47 | M | 9 | No need | No need | 4.1 | 3.2 | 1.3 | 392 | – | 8 |
| 2 | 56 | M | 8 | LFNC | LFNC | 16.4 | 53.9 | 0.8 | 349 | DXM, TCZ | 9 |
| 3 | 57 | M | 3 | No need | LFNC | 14.4 | – | 0.7 | 328 | DXM | 7 |
| 4 | 61 | M | 10 | No need | No need | 9.8 | 26.8 | 1.2 | 729 | – | 8 |
| 5 | 53 | M | 6 | No need | No need | 2.5 | – | 0.6 | 952 | DXM | 7 |
| 6 | 49 | M | 5 | LFNC | LFNC | 4.6 | 16.0 | 1.1 | 302 | DXM | 7 |
| 7 | 57 | F | 8 | No need | No need | 2.7 | 6.2 | 1.6 | 306 | – | 6 |
| 8 | 64 | M | 9 | LFNC | LFNC | 8.5 | 10.2 | 1.0 | 910 | – | 5 |
| 9 | 56 | M | 5 | No need | LFNC | 10.6 | 21.7 | 1.4 | 445 | – | 7 |
| 10 | 53 | M | 8 | LFNC | LFNC | 2.1 | 37.4 | 1.4 | 453 | DXM | 8 |
| 11 | 50 | M | 10 | No need | No need | 6.4 | 25.7 | 1.0 | 409 | – | 4 |
| 12 | 39 | M | 8 | LFNC | Mask | 6.5 | 26.9 | 1.5 | 307 | DXM, TCZ | 13 |
| 13 | 56 | F | 6 | LFNC | LFNC | 14.4 | 3.6 | 1.0 | 709 | DXM | 7 |
| 14 | 61 | F | 5 | LFNC | LFNC | 11.1 | 1.5 | 1.2 | 475 | DXM, RDV | 9 |
| 15 | 53 | M | 3 | LFNC | Mask | 30.6 | 237.0 | 0.9 | 630 | DXM, TCZ | 18 |
| 16 | 65 | M | 5 | LFNC | IMV | 15.1 | 91.0 | 1.0 | 396 | DXM, TCZ | 41 |
| 17 | 40 | M | 7 | No need | No need | 6.2 | 24.5 | 1.3 | 911 | – | 7 |
| 18 | 65 | F | 8 | No need | LFNC | 13.2 | 29.3 | 1.2 | 882 | DXM | 11 |
| 19 | 53 | F | 10 | No need | No need | 7.7 | 18.6 | 1.2 | 571 | – | 5 |
| 20 | 53 | M | 9 | No need | No need | 4.6 | 12.6 | 1.0 | 313 | DXM | 7 |
| 21 | 50 | M | 7 | LFNC | LFNC | 8.6 | 27.0 | 1.4 | 561 | – | 5 |
| 22 | 51 | M | 10 | No need | LFNC | 13.4 | 109.2 | 0.6 | 238 | DXM, TCZ | 9 |
| 23 | 64 | F | 8 | No need | LFNC | 4.5 | 19.0 | 1.4 | 449 | DXM | 7 |
| 24 | 54 | M | 9 | LFNC | LFNC | 10.9 | 106.0 | 1.1 | 445 | DXM, TCZ | 6 |
| 25 | 60 | M | 5 | No need | LFNC | 6.0 | 18.0 | 1.2 | 551 | DXM, RDV | 7 |
| 26 | 51 | M | 6 | LFNC | LFNC | 9.2 | 145.5 | 0.8 | 458 | DXM, TCZ | 6 |
| 27 | 60 | M | 6 | No need | LFNC | 2.1 | 26.4 | 1.3 | 150 | DXM, TCZ | 12 |
| 28 | 69 | F | 9 | LFNC | LFNC | 12.3 | – | 0.7 | 505 | DXM | 8 |
| 29 | 57 | M | 7 | LFNC | Mask | 8.4 | 35.1 | 0.8 | 390 | DXM, TCZ | 12 |
| 30 | 35 | M | 6 | No need | No need | 7.1 | 391.0 | 1.2 | 522 | DXM | 6 |
Abbreviations: yr = years; M = male; F = female; LFNC = low-flow nasal cannula; Mask = Venturi mask or nonrebreather face mask; IMV = invasive mechanical ventilation; DXM = dexamethasone; TCZ = tocilizumab; RDV = remdesivir. Reference ranges for C-reactive protein, interleukin-6 and D-dimer: < 0.5 mg/dL, < 7 pg/mL and < 500 ng/mL, respectively.
⁎
Days from symptom onset to treatment with imatinib.
†
Highest oxygen therapy support needed after imatinib onset.